Nevertheless, it is important to consider the spatial heterogeneity of the tumor immune microenvironment in BM compared to PPT, especially PD-L1 expression, when cancer patients are treated with PD-1 or PD-L1 inhibitors. This evidence concerns the gene CD274 and neoplasm.